Results 91 to 100 of about 53,113 (297)

A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: an application for bladder cancer treatment [PDF]

, 2016
Stealth pH-responsive liposomes for the delivery of therapeutic proteins to the bladder epithelium were prepared using methoxy-poly(ethylene glycol)5kDa-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (mPEG5kDa-DSPE) and stearoyl-poly(ethylene glycol ...
Balasso, Anna, Codolo, Gaia, DE BERNARD, Marina, Fassan, Matteo, Malfanti, Alessio, Munari, Fabio, Rugge, Massimo, Salmaso, Stefano, Vila Caballer, Marian   +8 more
core   +1 more source

Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab [PDF]

, 2023
Arash Nabbi, Arnavaz Danesh, Osvaldo Espin‐Garcia, Stephanie Pedersen, Johanna Wellum, Lingyan Helen Fu, Joseph N. Paulson, Birgit Geoerger, Lynley V. Marshall, Tanya Trippett, Gianluca Rossato, Trevor J. Pugh, Katherine E. Hutchinson   +12 more
openalex   +1 more source

Organ‐sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision‐making

International Journal of Cancer, EarlyView.
Abstract Deficiency in DNA mismatch repair (dMMR) is a common pathway of carcinogenesis across different tumor types and confers a characteristic microsatellite instability‐high (MSI‐H) molecular phenotype. The MSI‐H/dMMR phenotype may arise from an inherited pathogenic variant in the context of Lynch syndrome and is most frequently observed in ...
Martin Duval, Antoine Dardenne, Thomas Samaille, Leo Mas, Jérémie H. Lefèvre, Xavier Dray, Mathilde Wagner, Romain Cohen, Thierry André   +8 more
wiley   +1 more source

Cardiotoxicity of immune checkpoint inhibitors [PDF]

, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity.
Allison, Atkins, Azuma, Azuma, Baban, Badros, Bellmunt, Bloom, Borghaei, Boussiotis, Boutros, Brahmer, Brahmer, Bretscher, Brunet, Buchbinder, Cardinale, Cardinale, Chen, Chen, Chen, Cooper, Corsello, Costa, Ding, Dong, Dong, Douglas, Dyck, Eigentler, Fehrenbacher, Francisco, Freeman, Freeman, Gagliani, Gangadhar, Garon, Gay, Geisler, Gibson, Goodman, Gordon, Grabie, Hamanishi, Hamid, Hamo, Han, Hathcock, Heinzerling, Herbst, Herbst, Hodi, Hofmann, Huang, Hurst, Jain, Johnson, Johnson, Johnston, Keir, Khan, Koelzer, Lacouture, Larkin, Lasaro, Latchman, Le Mercier, Le Mercier, Leach, Lesokhin, Lines, Linsley, Linsley, Lucas, Läubli, Mahoney, Martin, Matsuzaki, Menzies, Michot, Mohme, Moslehi, Moynihan, Naidoo, Nayak, Nghiem, Nguyen, Ni, Nishimura, Nishimura, Okamura, Okazaki, Okazaki, Pardoll, Peggs, Pitt, Postow, Powles, Prashanth, Ribas, Rittmeyer, Rizvi, Robert, Robert, Roth, Sakuishi, Semper, Sharma, Sharma, Sheppard, Sivan, Smyth, Spain, Stanietsky, Suter, Tadokoro, Tadokoro, Tarrio, Tivol, Tocchetti, Tocchetti, Topalian, Topalian, Tumeh, Voskens, Vétizou, Wang, Wang, Watanabe, Waterhouse, Weber, Westin, Wing, Wolchok, Woo, Yan, Yeh, Yokosuka, Yu, Yun, Zitvogel   +140 more
core   +1 more source

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis [PDF]

, 2022
Xiaoyan Liu, Yitian Lang, Qingqing Chai, Yan Lin, Yahui Liao, Yi Zhun Zhu   +5 more
openalex   +1 more source

PD‐1/PD‐L1 in Hepatocellular Carcinoma (2014–2024): A Combined Macro and Micro Analysis of Immunotherapy Implications

iNew Medicine, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu, Lin Tang, Hongyan Li, Hao Li, Jiamei Wang   +4 more
wiley   +1 more source

Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study

BMJ Open
Objective Atezolizumab plus bevacizumab demonstrates a significant improvement in overall survival and progression-free survival compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC).
Lei Wang, Lulu Liu, Yiling Ding, Qilin Zhang, Yamin Shu   +4 more
doaj   +1 more source

Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model [PDF]

, 2020
Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model Jamie-Jean Gilmer, Depts. of Biology and Chemistry, with Dr. Sarah Golding, Dept.
Gilmer, Jamie-Jean
core   +1 more source

Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors

Interdisciplinary Medicine, EarlyView.
Napabucasin reduces liver metastases by reprogramming the hepatic microenvironment. It induces hepatocyte secretion of CCL21 via c‐Fos activation, recruiting lymphocytes and converting “cold” metastases into immunologically “hot” tumors. This effect is liver‐specific and independent of cancer cells.
Qiongqiong Wang, Jiaqi Zhou, Hang Qiao, Yifan Jia, Ling Ye, Zeli Li, Jiahe Ouyang, Haoxian Zhou, Kangxin Zeng, Xuemeng Wang, Yixian Wang, Yang Zhang, Yupeng Zhang, Yizhou Cai, Yutao Hu, Minzhe Zhang, Wenwei Xu, Zhenzhen Wu, Xiaofang Qiu, Li Lin   +19 more
wiley   +1 more source

Impact of Baseline Nutritional Status, Psychological Health, Fatigue, and Insomnia on Outcomes of Immune Checkpoint Inhibitors in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study investigated the impact of pretreatment nutritional status, psychological health, fatigue, and insomnia on outcomes of immune checkpoint inhibitors (ICIs) monotherapy in patients with advanced non‐small cell lung cancer (NSCLC). A total of 80 patients with stage IV NSCLC were enrolled.
Yu‐Xuan Zhu, Yuan‐Yuan Zhang, Xiu‐Juan Jiang   +2 more
wiley   +1 more source